183 related articles for article (PubMed ID: 32610710)
1. MHC Class I-Restricted TCR-Transgenic CD4
Schober SJ; Thiede M; Gassmann H; Prexler C; Xue B; Schirmer D; Wohlleber D; Stein S; Grünewald TGP; Busch DH; Richter GHS; Burdach SEG; Thiel U
Cells; 2020 Jun; 9(7):. PubMed ID: 32610710
[TBL] [Abstract][Full Text] [Related]
2. Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.
Blaeschke F; Thiel U; Kirschner A; Thiede M; Rubio RA; Schirmer D; Kirchner T; Richter GHS; Mall S; Klar R; Riddell S; Busch DH; Krackhardt A; Grunewald TG; Burdach S
Oncotarget; 2016 Jul; 7(28):43267-43280. PubMed ID: 27281613
[TBL] [Abstract][Full Text] [Related]
3. Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.
Schirmer D; Grünewald TG; Klar R; Schmidt O; Wohlleber D; Rubío RA; Uckert W; Thiel U; Bohne F; Busch DH; Krackhardt AM; Burdach S; Richter GH
Oncoimmunology; 2016 Jun; 5(6):e1175795. PubMed ID: 27471654
[TBL] [Abstract][Full Text] [Related]
4. STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors.
Grunewald TG; Diebold I; Esposito I; Plehm S; Hauer K; Thiel U; da Silva-Buttkus P; Neff F; Unland R; Müller-Tidow C; Zobywalski C; Lohrig K; Lewandrowski U; Sickmann A; Prazeres da Costa O; Görlach A; Cossarizza A; Butt E; Richter GH; Burdach S
Mol Cancer Res; 2012 Jan; 10(1):52-65. PubMed ID: 22080479
[TBL] [Abstract][Full Text] [Related]
5. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.
Kirschner A; Thiede M; Blaeschke F; Richter GH; Gerke JS; Baldauf MC; Grünewald TG; Busch DH; Burdach S; Thiel U
Oncotarget; 2016 Aug; 7(35):56584-56597. PubMed ID: 27447745
[TBL] [Abstract][Full Text] [Related]
6. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.
Ghorashian S; Veliça P; Chua I; McNicol AM; Carpenter B; Holler A; Nicholson E; Ahmadi M; Zech M; Xue SA; Uckert W; Morris E; Chakraverty R; Stauss HJ
J Immunol; 2015 Feb; 194(3):1080-9. PubMed ID: 25539815
[TBL] [Abstract][Full Text] [Related]
7. Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.
Altvater B; Kailayangiri S; Theimann N; Ahlmann M; Farwick N; Chen C; Pscherer S; Neumann I; Mrachatz G; Hansmeier A; Hardes J; Gosheger G; Juergens H; Rossig C
Cancer Immunol Immunother; 2014 Oct; 63(10):1047-60. PubMed ID: 24973179
[TBL] [Abstract][Full Text] [Related]
8. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
9. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
10. Fully functional HLA B27-restricted CD4+ as well as CD8+ T cell responses in TCR transgenic mice.
Roddis M; Carter RW; Sun MY; Weissensteiner T; McMichael AJ; Bowness P; Bodmer HC
J Immunol; 2004 Jan; 172(1):155-61. PubMed ID: 14688321
[TBL] [Abstract][Full Text] [Related]
11. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
12. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
13. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
14. TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.
Schober SJ; Thiede M; Gassmann H; von Ofen AJ; Knoch P; Eck J; Prexler C; Kordass-Wally C; Hauer J; Burdach S; Holm PS; Thiel U
Front Immunol; 2024; 15():1330868. PubMed ID: 38318175
[TBL] [Abstract][Full Text] [Related]
15. The development and functions of CD4(+) T cells expressing a transgenic TCR specific for an MHC-I-restricted tumor antigenic epitope.
Han X; Ye P; Luo L; Zheng L; Liu Y; Chen L; Wang S
Cell Mol Immunol; 2011 Jul; 8(4):333-40. PubMed ID: 21643003
[TBL] [Abstract][Full Text] [Related]
16. Cross-positive selection of thymocytes expressing a single TCR by multiple major histocompatibility complex molecules of both classes: implications for CD4+ versus CD8+ lineage commitment.
Eshima K; Suzuki H; Shinohara N
J Immunol; 2006 Feb; 176(3):1628-36. PubMed ID: 16424192
[TBL] [Abstract][Full Text] [Related]
17. Cellular mechanisms involved in protection against influenza virus infection in transgenic mice expressing a TCR receptor specific for class II hemagglutinin peptide in CD4+ and CD8+ T cells.
Bot A; Casares S; Bot S; von Boehmer H; Bona C
J Immunol; 1998 May; 160(9):4500-7. PubMed ID: 9574556
[TBL] [Abstract][Full Text] [Related]
18. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
Manning TC; Rund LA; Gruber MM; Fallarino F; Gajewski TF; Kranz DM
J Immunol; 1997 Nov; 159(10):4665-75. PubMed ID: 9366389
[TBL] [Abstract][Full Text] [Related]
19. Ikaros null mice display defects in T cell selection and CD4 versus CD8 lineage decisions.
Urban JA; Winandy S
J Immunol; 2004 Oct; 173(7):4470-8. PubMed ID: 15383578
[TBL] [Abstract][Full Text] [Related]
20. Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers.
Jin Y; Dunn C; Persiconi I; Sike A; Skorstad G; Beck C; Kyte JA
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
